title: [A clinical study of pelvic floor electrical stimulation in treatment of overactive bladder].
abstract: OBJECTIVE
  To observe the efficacy of electrical stimulation in treatment of overactive bladder (OAB).
  
  
  METHODS
  Patients (n = 60) with overactive bladder were randomly divided into 2 groups. Electrical stimulation group (n = 35) used an instrument for electrical stimulation through a special vagina or rectum probe transfer current (8-70 mA), for 20 min, qd, for 20-30 times. Medical group (n = 25) received oral tolterodine 2 mg, bid, for 2-4 weeks.
  
  
  RESULTS
  The total effective rate and cure rate were 74%, 37% in electrical stimulation group and 76%, 40% in medical group, respectively, showing no significant difference between two groups (P > 0.05). While patients' satisfactory rate was significantly higher in electrical stimulation group than in medical group (P < 0.05). Side effects were more commonly seen with tolterodine.
  
  
  CONCLUSIONS
  Electrical nerve stimulation is effective and safe for overactive bladder. Further studies are needed to show the long term efficacy and cost-effectiveness.
authors.affiliation: Department of Obstetrics and Gynecology, Fuzhou General Hospital, Nanjing Military Command, Fuzhou 350025, China.
authors.forename: Li-sha
authors.initials: LS
authors.lastname: Lin
authors.forename: Yan-feng
authors.initials: YF
authors.lastname: Song
authors.forename: Jian
authors.initials: J
authors.lastname: Song
authors.forename: Mei-fang
authors.initials: MF
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D003248:Constipation / Q000209:etiology; D003408:Cresols / Q000009:adverse effects / Q000627:therapeutic use; D004599:Electric Stimulation Therapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017773:Pelvic Floor / Q000503:physiopathology; D010665:Phenylpropanolamine / Q000009:adverse effects / Q000627:therapeutic use; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy / Q000628:therapy*; D014554:Urination / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy / Q000628:therapy*; D014987:Xerostomia / Q000209:etiology
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate